Access to Orkambi and Symkevi Agreed in England
Cystic Fibrosis Ireland (CFI) congratulates the UK CF Trust in successfully advocating for CF drug therapy ‘ Orkambi' in England.
CFI hopes that CF patients in Northern Ireland (and Wales) will be given equal access to Orkambi as soon as possible.
After a considerable delay, people with CF in England have finally been granted access to Orkambi, the first drug to treat the underlying condition for over half of CF patients in the UK. CF patients in Ireland were granted access to Orkambi in in April 2017. Orkambi has now been approved in Ireland, Scotland, England, Italy, Sweden, the Netherlands, Italy, Austria, Denmark the US and Australia.
Philip Watt, CEO of CFI, stated
‘We would hope that patients in Northern Ireland (and Wales) will be granted access to Orkambi as soon as possible. It is extremely funfair for patients and their families in Northern Ireland to be continued to be denied Orkambi, particularly when they know it is available south of the border. Many congratulations to the UK Trust and in particular their CEO David Ramsden for this breakthrough for CF patients in England.’